How Meeker was paid
$17.5M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| David P. MeekerChief Executive Officer | $807,692 | $8,274,785 | $7,688,560 | $759,488 | $14,000 | $17,544,525 |
| Hunter C. SmithChief Financial Officer | $540,477 | $2,933,277 | $2,402,675 | $338,000 | $14,000 | $6,228,429 |
| Jennifer LeeExecutive Vice President, Head of North America | $531,635 | $2,649,827 | $2,114,354 | $293,000 | $14,000 | $5,602,816 |
| Yann MazabraudExecutive Vice President, Head of International | $557,231 | $2,839,739 | $2,306,568 | $344,659 | $70,258 | $6,118,455 |
| Alastair GarfieldChief Scientific Officer | $505,385 | $2,082,927 | $1,537,712 | $287,000 | $14,000 | $4,427,024 |
What changed and why
- $194.8MGlobal net product revenues increased by approximately 50% year-over-year to reach $194.8 million in 2025.
- 120%The Board approved a 120% corporate achievement factor for the 2025 annual bonus plan.
- 100%The CEO's 2026 bonus award will be calculated based on 100% corporate achievement with no individual performance component.
- 50%The executive long-term incentive grant mix consists of 50% stock options and 50% restricted stock units.
- The FDA approved an expanded indication for IMCIVREE to treat patients living with acquired hypothalamic obesity.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.